Published in Br J Haematol on January 09, 2014
Regulation of hematopoietic and leukemic stem cells by the immune system. Cell Death Differ (2014) 1.10
Novel drugs for older patients with acute myeloid leukemia. Leukemia (2014) 0.99
Role of Microenvironment in Resistance to Therapy in AML. Curr Hematol Malig Rep (2015) 0.92
Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia. Cell Cycle (2014) 0.89
Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood (2015) 0.86
CD44, Hyaluronan, the Hematopoietic Stem Cell, and Leukemia-Initiating Cells. Front Immunol (2015) 0.84
New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine. Clin Cancer Res (2014) 0.83
Stem Cell Hierarchy and Clonal Evolution in Acute Lymphoblastic Leukemia. Stem Cells Int (2015) 0.82
Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. Blood (2016) 0.80
Histone Deacetylase Inhibitors Target the Leukemic Microenvironment by Enhancing a Nherf1-Protein Phosphatase 1α-TAZ Signaling Pathway in Osteoblasts. J Biol Chem (2015) 0.79
Are neural crest stem cells the missing link between hematopoietic and neurogenic niches? Front Cell Neurosci (2015) 0.77
FZD7 regulates BMSCs-mediated protection of CML cells. Oncotarget (2016) 0.77
Hypoxia and Hypoxia-Inducible Factors in Leukemias. Front Oncol (2016) 0.76
Bone Marrow Recovery by Morphometry during Induction Chemotherapy for Acute Lymphoblastic Leukemia in Children. PLoS One (2015) 0.76
Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang. Cancer Biol Med (2016) 0.76
Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality? Int J Mol Sci (2016) 0.76
The Hematopoietic Niche in Myeloproliferative Neoplasms. Mediators Inflamm (2015) 0.76
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells. Oncotarget (2016) 0.75
Survival of acute monocytic leukemia cells is driven by fatty acid oxidation-mediated activation of AMPK in bone marrow adipocytes. Cancer Res (2017) 0.75
Osteoblasts as leukemia-initiating cells. Bonekey Rep (2014) 0.75
Growth of tyrosine kinase inhibitor-resistant Philadelphia-positive acute lymphoblastic leukemia: Role of bone marrow stromal cells. Oncol Lett (2017) 0.75
Understanding leukemic hematopoiesis as a complex adaptive system. World J Stem Cells (2015) 0.75
Relevance of epithelial-to-pericyte transition in cancer. Mol Cell Oncol (2016) 0.75
Cytokines secreted by bone marrow stromal cells protect c-KIT mutant AML cells from c-KIT inhibitor-induced apoptosis. Leukemia (2014) 0.75
Immunological effects of vaccines combined with granulocyte colony-stimulating factor on a murine WEHI-3 leukemia model. Oncol Lett (2017) 0.75
Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia. Oncotarget (2015) 0.75
Modeling of Chronic Myeloid Leukemia: An Overview of In Vivo Murine and Human Xenograft Models. Stem Cells Int (2016) 0.75
Epithelial-to-Pericyte Transition in Cancer. Cancers (Basel) (2017) 0.75
Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther (2017) 0.75
Bone marrow fibrosis at diagnosis predicts survival for primary acute myeloid leukemia. Clin Transl Oncol (2017) 0.75
The Role of the Central Nervous System Microenvironment in Pediatric Acute Lymphoblastic Leukemia. Front Pediatr (2017) 0.75
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
The biology of VEGF and its receptors. Nat Med (2003) 32.13
SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell (2005) 24.00
Osteoblastic cells regulate the haematopoietic stem cell niche. Nature (2003) 19.60
Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature (2010) 15.28
Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell (2004) 12.67
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature (2006) 11.86
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med (2004) 11.71
Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity (2006) 11.28
Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature (1996) 10.67
The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells (1978) 8.80
Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 8.71
Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell (2006) 7.23
Endothelial and perivascular cells maintain haematopoietic stem cells. Nature (2012) 6.60
Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med (2006) 5.92
Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J Exp Med (2005) 5.68
Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature (2003) 5.57
Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature (2005) 5.54
Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature (2010) 5.43
Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med (2006) 5.33
A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell (2007) 4.59
Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol (2008) 4.42
The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science (2010) 4.37
Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell (2007) 4.21
Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood (2005) 4.17
The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity (2010) 4.13
Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell (2011) 4.04
Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J Exp Med (2011) 3.88
Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell (2007) 3.82
Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood (2008) 3.77
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood (2008) 3.67
Normal stem cells and cancer stem cells: the niche matters. Cancer Res (2006) 3.60
No place like home: anatomy and function of the stem cell niche. Nat Rev Mol Cell Biol (2008) 3.46
Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science (2008) 3.39
A VCAM-like adhesion molecule on murine bone marrow stromal cells mediates binding of lymphocyte precursors in culture. J Cell Biol (1991) 3.23
Arteriolar niches maintain haematopoietic stem cell quiescence. Nature (2013) 3.07
Metabolic regulation of hematopoietic stem cells in the hypoxic niche. Cell Stem Cell (2011) 3.05
CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood (2004) 2.84
Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med (2006) 2.69
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol (2012) 2.59
Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol (2011) 2.52
Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell (2013) 2.46
In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature (2011) 2.44
Quantitative imaging of haematopoietic stem and progenitor cell localization and hypoxic status in the bone marrow microenvironment. Nat Cell Biol (2013) 2.34
Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. Blood (2009) 2.25
Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev (2008) 2.12
Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci U S A (2011) 2.08
High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br J Haematol (2001) 2.06
Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest (2007) 2.05
Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood (2004) 2.05
Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood (2008) 1.98
Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood (2000) 1.93
Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood (2013) 1.79
Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood (2000) 1.76
Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther (2006) 1.74
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling. Blood (2013) 1.70
Oxygen saturation in the bone marrow of healthy volunteers. Blood (2002) 1.58
Concepts of human leukemic development. Oncogene (2004) 1.56
VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood (2002) 1.56
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther (2008) 1.52
CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann N Y Acad Sci (2000) 1.52
Hematopoietic stem cell mobilization: updated conceptual renditions. Leukemia (2012) 1.49
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther (2008) 1.49
Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer (2007) 1.46
The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow. Exp Hematol (2001) 1.46
CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood (2008) 1.44
In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell (2013) 1.42
BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res (2012) 1.42
Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia (2003) 1.40
Cancer stem cells and their niche. Cancer Sci (2009) 1.39
Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo. Blood (2010) 1.37
CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (Maywood) (2013) 1.30
Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res (2000) 1.28
Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow. J Exp Med (2012) 1.28
Chemotherapy-induced bone marrow nerve injury impairs hematopoietic regeneration. Nat Med (2013) 1.25
Stem cell integrins: implications for ex-vivo culture and cellular therapies. Stem Cell Res (2010) 1.24
Disrupting the stem cell niche: good seeds in bad soil. Cell (2007) 1.23
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One (2011) 1.23
Stroma-mediated dysregulation of myelopoiesis in mice lacking I kappa B alpha. Immunity (2005) 1.21
Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. Mol Cancer Ther (2006) 1.20
Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia. Br J Haematol (2000) 1.19
Prognostic evaluation of the microvascular network in myelodysplastic syndromes. Leukemia (2001) 1.16
The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells. Adv Hematol (2013) 1.09
Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. Blood (2013) 1.08
Control of hematopoietic stem cells by the bone marrow stromal niche: the role of reticular cells. Trends Immunol (2011) 1.08
Changing bone marrow micro-environment during development of acute myeloid leukaemia in rats. Br J Haematol (1998) 1.05
Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats. Cell Prolif (2000) 1.04
Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia (2004) 1.01
Immature leukemic CD34+CXCR4+ cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1. Stem Cells (2002) 1.00
Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts. Leukemia (2011) 0.96
Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. Clin Cancer Res (2001) 0.92
Silicate modulates the cross-talk between osteoblasts (SaOS-2) and osteoclasts (RAW 264.7 cells): inhibition of osteoclast growth and differentiation. J Cell Biochem (2012) 0.92
CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not. Blood (2002) 0.91
The biology of CD44 and HCELL in hematopoiesis: the 'step 2-bypass pathway' and other emerging perspectives. Curr Opin Hematol (2011) 0.90
TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment. PLoS One (2013) 0.89
Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia? Semin Cancer Biol (2010) 0.89
Stromal abnormalities in neoplastic bone marrow diseases. Ann Hematol (1996) 0.89
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology (2009) 4.72
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood (2008) 3.67
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med (2010) 3.26
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood (2006) 3.13
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood (2005) 2.88
Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest (2009) 2.80
Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol (2009) 2.78
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst (2008) 2.77
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov (2013) 2.74
Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood (2006) 2.45
Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2012) 2.45
Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med (2007) 2.38
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res (2006) 2.23
A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res (2006) 1.92
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol (2009) 1.83
Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma (2012) 1.80
Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther (2006) 1.74
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood (2013) 1.70
Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res (2007) 1.67
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica (2010) 1.65
Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res (2013) 1.61
The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling. Cancer Res (2007) 1.60
Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma. Acta Haematol (2013) 1.51
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther (2008) 1.49
Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer (2007) 1.46
Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a. Mol Pharmacol (2010) 1.44
The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr(db/db) mice. J Biol Chem (2010) 1.44
Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res (2003) 1.43
A novel mechanism of action of methyl-2-cyano-3,12 dioxoolean-1,9 diene-28-oate: direct permeabilization of the inner mitochondrial membrane to inhibit electron transport and induce apoptosis. Mol Pharmacol (2006) 1.41
Expression of inducible Bcl-X(S) in myeloid leukemia: compensatory upregulation of Bcl-X(L) and Bcl-2 prevents apoptosis and chemosensitization. Cancer Biol Ther (2004) 1.39
CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clin Invest (2013) 1.35
2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer. J Biol Chem (2005) 1.32
2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathways. Mol Pharmacol (2005) 1.32
Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance. Blood (2014) 1.29
Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res (2006) 1.25
Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood (2012) 1.25
Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment. Blood (2012) 1.25
Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy (2010) 1.24
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One (2011) 1.23
Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood (2002) 1.23
Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. Cell Cycle (2006) 1.21
A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res (2012) 1.21
Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res (2007) 1.18
PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood (2003) 1.17
Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res (2003) 1.15
Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood (2012) 1.14
Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival. Stem Cells (2004) 1.11
Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors. Cancer Res (2006) 1.11
The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells. Adv Hematol (2013) 1.09
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant (2011) 1.09
Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells. Cancer Res (2007) 1.09
Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant (2007) 1.07
Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment. Blood (2013) 1.03
Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle (2012) 1.03
Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer (2011) 1.02
CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. Blood (2007) 1.00
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther (2009) 1.00
Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell Cycle (2006) 0.99
Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expression. Gynecol Oncol (2004) 0.99
Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia. Cancer Res (2010) 0.99
MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Cancer Lett (2010) 0.98
High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood (2007) 0.98
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer (2014) 0.98
Triterpenoids display single agent anti-tumor activity in a transgenic mouse model of chronic lymphocytic leukemia and small B cell lymphoma. PLoS One (2007) 0.98
BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia. Mol Cancer Ther (2013) 0.97
Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells. Mol Cancer Ther (2008) 0.97
Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione structure. Mol Cancer Ther (2005) 0.97
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia. Am J Hematol (2013) 0.96
Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther (2012) 0.96
Mesenchymal Stem Cells Overexpressing IFN-β Inhibit Breast Cancer Growth and Metastases through Stat3 Signaling in a Syngeneic Tumor Model. Cancer Microenviron (2010) 0.95
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry A (2015) 0.95
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol (2015) 0.95
Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol (2012) 0.94
XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis (2011) 0.94
Role of Microenvironment in Resistance to Therapy in AML. Curr Hematol Malig Rep (2015) 0.92
SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. Br J Haematol (2014) 0.92
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood (2013) 0.92
A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk (2012) 0.92
The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo. PLoS One (2013) 0.91
MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood (2006) 0.91
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies. J Mol Med (Berl) (2012) 0.91
Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK. Cell Cycle (2008) 0.91
Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells. J Cell Biochem (2011) 0.89
TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment. PLoS One (2013) 0.89
Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma (2014) 0.89
Mitochondrial uncoupling and the reprograming of intermediary metabolism in leukemia cells. Front Oncol (2013) 0.89
Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia. Cancer (2011) 0.89
Evidence supporting a role for calcium in apoptosis induction by the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO). J Biol Chem (2004) 0.88
PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL. Cancer Biol Ther (2007) 0.87
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell (2016) 0.87